Immuno-checkpoint inhibitor (ICI) is becoming an integral part of advanced cancer treatment. ICI can cause adverse events in multiple organs more commonly in skin and GI tract. ICI-induced colitis (ICI-C) can be mild or severe and lead to cessation of cancer treatment. There is insufficient information about the optimal treatment for ICI-C. Based on published case series, ICI-C can improve with high dose steroids as first line and infliximab or vedolizumab as second line treatment. Here, we describe an alternative promising treatment for ICI-C resulted in an excellent outcome.